Promising combo aims to boost remission in rare blood cancer
NCT ID NCT05376111
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining venetoclax with azacitidine can help people with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) achieve remission. About 28 participants aged 15 and older will receive the drug combination for up to two 21-day cycles. The main goal is to see how many patients respond, while also tracking side effects and long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECRUITING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized chemo dosing may boost survival in kids with High-Risk leukemia
- Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
- Engineered immune cells take aim at stubborn blood cancers
- Double-Barreled immune attack aims to wipe out T-ALL
- Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
- Gene test spots hidden leukemia in kids